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Edited by Gianni CesareniAbstract TANK-binding kinase 1 (TBK1) was identiﬁed as a
binding partner for Optineurin (OPTN) in two-hybrid screens,
an interaction conﬁrmed by overexpression/immunoprecipitation
experiments in HEK293 cells and by coimmunoprecipitation of
endogenous OPTN and TBK1 from cell extracts. A TBK1 bind-
ing site was located between residues 1-127 of OPTN, residues
78-121 displaying striking homology to the TBK1-binding do-
main of TANK. The OPTN-binding domain was localised to res-
idues 601-729 of TBK1, while TBK1[1-688] which cannot bind to
TANK, did not interact with OPTN. The OPTN[E50K] mutant
associated with Primary Open Angle Glaucoma (POAG) dis-
played strikingly enhanced binding to TBK1, suggesting that this
interaction may contribute to familial POAG caused by this
mutation.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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IKK1. Introduction
Primary open angle glaucoma (POAG) is a leading cause of
irreversible blindness aﬀecting over 30 million people world-
wide. The disease is genetically heterogeneous and mutations
in the protein optineurin (OPTN) have been found to cause
or to be a risk factor for familial POAG associated with nor-
mal intraocular pressure, termed normal tension glaucoma
(NTG) [1,2]. An initial study of 54 families with autosomal
dominant adult onset glaucoma, showed that 10 had one of
four sequence mutations in OPTN, the most prevalent being
the OPTN[E50K] mutant. Subsequent studies with larger num-
ber of patients conﬁrmed the association of OPTN[E50K] with
familial NTG in some human populations [3–5]. Tumour
necrosis factor a (TNFa) increases the severity of damage to
the optic nerve heads of POAG and NTG subjects [6,7] and
exposure to TNFa induces the de novo expression of OPTN
[8], suggesting that some forms of POAG may be caused by
an abnormal response to this pro-inﬂammatory cytokine.
Here, we identify the TNFa-activated protein kinase TBK1
(TRAF-associated NFjB activator (TANK)-binding kinase-1)
as a novel binding partner for OPTN and identify a TBK1-*Corresponding author. Fax: +44 1382 223778.
E-mail addresses: p.cohen@dundee.ac.uk (P. Cohen), j.l.n.hare@
dundee.ac.uk (P. Cohen).
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doi:10.1016/j.febslet.2008.02.047binding domain in the N-terminal region of OPTN, which
shows striking homology to TBK1-binding domains present
in the other three known binding partners of TBK1, termed
TANK, NAP1 and SINTBAD. We also demonstrate that
OPTN binds to the C-terminal region of TBK1 and that dele-
tion of the C-terminal 40 residues of TBK1, which prevents
interaction with TANK, also abolishes interaction with
OPTN. Strikingly, we ﬁnd that the OPTN[E50K] mutant dis-
plays much stronger binding to TBK1 than wild-type OPTN,
and discuss whether this enhanced interaction could underlie
familial NTG caused by this OPTN mutation.2. Results and discussion
To identify proteins that interact with OPTN, yeast two hy-
brid screens were carried out using OPTN as bait. Approxi-
mately 1 · 106 yeast colonies were screened from a human
foetal brain cDNA library and a similar number from a human
leukocyte cDNA library. One positive clone was detected in
each library that interacted with OPTN and encoded the C-ter-
minal region of TBK1 (residues 572–729 from the brain library
and residues 601–729 from the leukocyte library, results not
shown). This ﬁnding was unexpected, since it had been re-
ported that neither of the two unidentiﬁed protein kinase activ-
ities associated with OPTN immunoprecipitates were TBK1
[8]. We therefore carried out further experiments to investigate
whether OPTN and TBK1 were capable of interacting with
one another.
In initial experiments, we studied the association between
OPTN and TBK1 by co-expression of vectors encoding gluta-
thione-S-transferase (GST) fused to TBK1 and haemaggluti-
nin (HA)-tagged OPTN in human embryonic kidney (HEK)
293 cells that stably express the Interleukin-1 (IL-1) receptor
(termed IL-1R cells). We found that the expressed HA-OPTN
could be ‘‘pulled down’’ on glutathione-Sepharose together
with GST-TBK1 (Fig. 1A), while GST-TBK1 could be immu-
noprecipitated with anti-HA antibodies (Fig. 1B). We also
showed that the endogenous TBK1 in IL-1R cells could be
immunoprecipitated with the endogenous OPTN (Fig. 1C),
although only a minor proportion of the TBK1 in the cell ex-
tracts was immunoprecipitated, indicating the presence of
other TBK1 complexes. The interaction between OPTN and
TBK1 was not aﬀected by stimulation with IL-1 (Fig. 1A–
C), which activates TBK1 in IL-1R cells (K. Clark and P. Co-
hen, unpublished experiments).
Strikingly, the amount of TBK1 bound to OPTN was
enhanced when wild-type (WT)-OPTN was replaced by theblished by Elsevier B.V. All rights reserved.
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Fig. 1. OPTN interacts with TBK1 in mammalian cells. (A) IL-1R cells were co-transfected with a vector expressing GST-TBK1 and either empty
vector (empty), or vectors expressing HA-OPTN (OPTN), HA-OPTN[E50K] (E50K) or HA-OPTN[R545Q] (R545Q). Cells were stimulated for
10 min with (+) or without () IL-1b (5 ng/ml), lysed and GST-TBK1 pulled down from the extracts and immunoblotted (IB) with anti-HA to detect
the presence of OPTN and with anti-GST to detect TBK1 as described under Section 3. (B) HA-OPTN was immunoprecipitated from the same
extracts used A and immunoblotted with anti-GST antibodies to detect TBK1 (C) untransfected IL-1R cells were stimulated with 5 ng/ml IL-1b for
the times indicated. Following cell lysis, endogenous OPTN was immunoprecipitated and immunoblotted with anti-GST to detect TBK1 and with
anti-OPTN. The cell lysate (80 lg protein) was also immunoblotted with antibodies that recognise the active, phosphorylated forms of ERK1 and
ERK2 (ERK1/2), to monitor stimulation by IL-1b. (D) As in A, except that cells were transfected with HA-tagged TBK1 and GST-tagged wild-type
or mutant OPTN. GST–OPTN pulled from the cell extracts, was immunoblotted (IB) with anti-HA to detect TBK1 and with anti-GST. (E) IL-1R
cells were transfected with vectors encoding HA-tagged wild-type (WT)-OPTN or OPTN[E50K] (E50K) and stimulated for 15 min with 5 ng/ml IL-
1b. HA-OPTN was immunoprecipitated from the extracts and bound proteins released by denaturation in SDS and immunoblotted with anti-TBK1
and anti-HA.
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(Fig. 1A and B). In contrast, the OPTN[R545Q] mutant, which
has been detected in a few individuals with POAG [1,4,5], but
does not show association with POAG in most populations
[4,5], interacted with TBK1 in a similar manner to WT-OPTN
(Fig. 1A and B). When the tags were reversed and vectors
expressing GST-OPTN were co-transfected with vectors
expressing HA-TBK1, the results were even more striking.
Only the GST-OPTN[E50K] mutant, but not WT-OPTN or
OPTN[R545Q], interacted with TBK1 (Fig. 1D). These exper-
iments suggested that the large GST-tag attached to the N-ter-
minus of OPTN interferes with binding to wild-type TBK1,
this interference being overcome, at least partially, in the OPT-
N[E50K] mutant, presumably as a result of a conformational
change.
Interestingly, when HA-OPTN or HA-OPTN[E50K] were
transfected into IL-1R cells and immunoprecipitated with
anti-HA, endogenous TBK1 was only associated with HA-
OPTN[E50K] and not HA-OPTN (Fig. 1E). These observa-
tions again indicated that HA-OPTN[E50K] binds TBK1 more
avidly than HA-OPTN and is therefore much more eﬃcient
than HA-OPTN at displacing TBK1 from its endogenous
binding partners in these cells. Similar results were obtained
with OPTN-HA with the tag attached to the C-terminus of
OPTN (results not shown). However, the overexpression of
HA-OPTN[E50K] or OPTN[E50K]-HA only bound a minorproportion of the TBK1 present in the cell extracts, indicating
the presence of other TBK1 complexes that are not disrupted
by the overexpression of OPTN[E50K]. This may explain
why the over-expression of either HA-OPTN or HA-OPT-
N[E50K] did not aﬀect the IL-1-stimulated activation of
TBK1 signiﬁcantly in IL-1R cells. The IL-1-stimulated activa-
tion of TBK1 was also unaﬀected by the complete ‘‘knock-
down’’ of the endogenous OPTN in IL-1R cells after
lentiviral-mediated transfection of an interfering shRNA (L.
Hesson, K. Clark and P. Cohen, results not shown).
One adult with POAG was found to have a two base pair
insertion in the OPTN gene that resulted in the expression of
a truncated protein in which only the N-terminal 127 residues
of OPTN were expressed [1]. We found that OPTN[1–127] in
which Glu50 had been changed to Lys interacted with TBK1
in co-transfection experiments (Fig. 2A), although OPTN[1–
127] without this mutation did not (results not shown). Never-
theless, this ﬁnding indicated that a binding site for TBK1 was
present within the N-terminal 127 residues of OPTN. We
therefore interrogated protein sequence databases with this re-
gion of OPTN to search for other proteins with sequence sim-
ilarities. Remarkably, this analysis revealed that the amino
acid sequence between residues 78–121 of OPTN, but no other
region of the protein, was homologous to the TBK1-interac-
tion domain present in the other three known binding partners
for TBK1, termed TANK [9], NAP1 (NFjB activating kinase
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Fig. 2. Characterisation of the interaction between OPTN and TBK1. (A) IL-1R cells were transfected as in Fig. 1 with vectors expressing GST-
TBK1 and HA-OPTN[1–127] in which Glu50 had been mutated to Lys (E50K) or HA-OPTN[1–127] in which Met98 had been mutated to Lys
(M98K). After 48 h, the cells were lysed and GST-TBK1 pulled down from the cell extract and immunoblotted with anti-HA to detect OPTN. The
membrane was stripped and re-probed with an antibody that recognizes GST. Cell lysate protein (50 lg) was also immunoblotted with anti-HA. (B)
Sequence alignment of the TBK1 interaction domains found in human (h) TANK, NAP1 and SINTBAD with OPTN. Identities are shown in white
lettering on a black background and similar residues in white lettering on a grey background. Met98 of OPTN is marked with an asterisk. (C) The
experiment was carried out as in A, except that the cells were transfected with vectors expressing GST-TBK1 and either empty vector (control), a
vector expressing full length wild-type OPTN (WT), a vector expressing HA-OPTN[E50K] (E50K) or a vector expressing HA-OPTN[M98K]
(M98K).
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Fig. 3. The C-terminal region of TBK1 is required for interaction with
OPTN. IL-1R cells were transfected with vectors expressing GST,
wild-type GST-TBK1 (WT) or GST-TBK1[1–687] (1–687) and vectors
expressing HA-tagged OPTN or HA-tagged TANK. The experiment
was then carried out exactly as described in the legend of Fig. 2.
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TBK1 adaptor) [11] (Fig. 2B). Interestingly, this region of
OPTN includes Met98 and the Met98Lys mutation has been
reported to show a statistical association with familial NTG
in some human populations [1,3–5], but not others [5,12].
However, unlike OPTN[E50K], OPTN[M98K] did not show
enhanced binding to TBK1 over the wild-type protein
(Fig. 2C) and, like OPTN[1–127], OPTN[1–127] in which
Met98 had been changed to Lys did not interact with TBK1
in co-transfection experiments (Fig. 2A).
The results described above suggested that OPTN, TANK,
NAP1 and SINTBAD share a common TBK1-binding domain
and therefore bind to the same region of TBK1. It has been re-
ported that deletion of the C-terminal 41 residues of TBK1
(residues 688–729) prevents interaction with TANK [9] and
we found that wild-type OPTN was also unable to bind to
TBK1[1–688] (Fig. 3). This is in agreement with the yeast
two-hybrid results described earlier, which showed that OPTN
interacted with the C-terminal 128 amino acid residues of
TBK1. Taken together, these results indicate that, like TANK,
NAP1 and SINTBAD, OPTN binds to the C-terminal region
of TBK1 and suggest that four TBK1 complexes may exist
in cells, namely TANK–TBK1, NAP1–TBK1, SINTBAD–
TBK1 and OPTN–TBK1. It will clearly be important to estab-
lish the relative proportions of the diﬀerent forms of TBK1 in
diﬀerent cell types, whether the OPTN–TBK1 complex is a ma-
jor form of TBK1 in optic nerve heads, and whether diﬀerent
TBK1 complexes are activated selectively by distinct agonists.
TBK1 is a member of the IjB kinase (IKK) subfamily of
protein kinases and is most similar to IKKe, with which it
shares 73% identity in the catalytic domain. TBK1 and IKKe
become activated in response to lipopolysaccharide (LPS) or
viral double-stranded DNA (dsRNA) and can then phosphor-ylate the transcription factor interferon regulatory factor 3
(IRF3), inducing its translocation to the nucleus where it stim-
ulates transcription of the genes encoding type-1 interferons
[13–15]. The ‘‘knock-out’’ of both TBK1 and IKKe is required
to suppress the LPS-or dsRNA-stimulated activation of IRF3
and production of Type 1 interferons in both conventional
dendritic cells and macrophages induced from foetal liver cells
(Matsui et al. [15]). However, in contrast to TBK1, we found
that IKKe did not interact with either OPTN or OPTN[E50K]
when these proteins were co-transfected into IL-1R cells (S.
Morton and P. Cohen, results not shown). The relatively low
similarity between the C-termini of TBK1 and IKKe (only
1000 S. Morton et al. / FEBS Letters 582 (2008) 997–100226% identity between residues 600 and 729) may explain why
IKKe is unable to interact with OPTN.
The protein most closely related to OPTN is NEMO (NFjB
essential modiﬁer), and for this reason OPTN has also been
termed NEMO-related protein (NRP) [8]. NEMO is the regu-
latory subunit of the IjBa kinase (IKK) complex containing
IKKa and IKKb, which activate the transcription factor
NFjB. In contrast to OPTN, NEMO does not interact directly
with TBK1 [16,17], presumably because it lacks the N-terminal
extension present in OPTN, and hence does not possess the
TBK1-binding site identiﬁed in this paper. Nevertheless,
NEMO can interact with TANK and is therefore associated
with the TANK–TBK1 complex [16]. This interaction appears
to facilitate the binding of TANK–TBK1 to the cytosolic RIG-
I RNA helicase that detects infection by intracellular RNA
viruses. In this process NEMO appears to facilitate the recruit-
ment of TANK–TBK1 to the RIG-I/MAVS/TRAF complexes
associated with the outer mitochondrial membrane [17].
NEMO contains a domain that binds to Lys63-linked poly-
ubiquitin (K63-pUb) chains, an interaction which is thought to
help recruit the IKK complex to K63-pUb-RIP (receptor inter-
acting protein) in response to TNFa. This seems to be required
for the eﬃcient activation of IKK by this agonist and hence the
activation of NFjB, because a mutation in the K63-pUb-bind-
ing domain of NEMO (NEMO[D311N]), which prevents inter-
action with K63-pUb chains in vitro and with K63-pUb-RIP
in cells [18,19], underlies X-linked anhidrotic ectodermal dys-
plasia [20], an immuno-deﬁciency disease associated with in-
creased susceptibility to mycobacterial infection [21]. The
K63-pUb-binding domain present in NEMO is conserved in
OPTN. As a consequence OPTN, like NEMO, binds to K63-
pUb chains in vitro and to K63-pUb-RIP in TNFa-stimulated
cells [22]. Moreover OPTN[D474N], the mutation equivalent
to NEMO[D311N], cannot bind K63-pUb chains in vitro or
interact with K63-pUb-RIP in cells [22]. Thus, one role for
OPTN may be to recruit TBK1 to K63-pUb-RIP in response
to TNFa and/or other K63-pUb proteins in response to other
agonists. The enhanced interaction between OPTN[E50K] and
TBK1 further suggests that more TBK1 may be recruited to
K63-pUb-RIP and/or other K63-pUb-proteins in cells that
express OPTN[E50K]. We are therefore generating mice that
express the OPTN[D474N] mutation to evaluate how the fail-
ure to bind K63-pUb chains aﬀects the function of OPTN.
TBK1 is recruited to the TNF receptor complex and acti-
vated in response to TNFa [23,24], and TNFa increases the
severity of damage to the optic nerve heads of subjects with
POAG and NTG [6,7]. Moreover, mice that do not express
TBK1 die just prior to birth because they become hypersensi-
tive to TNFa-induced apoptosis of the liver and lethality can
be rescued by crossing to mice that do not express TNF Recep-
tor 1 [23]. Furthermore, the adenovirus E3-14.7K protein
binds to OPTN, and this interaction blocks the protective ef-
fect of the E3-14.7K protein on TNFa-induced apoptosis
[25]. Taken together, these observations indicate that OPTN
and TBK1, perhaps by operating as a complex, play critical
roles in the regulation of TNFa-stimulated apoptosis. They
also suggest that the OPTN[E50K] mutant may cause aberrant
activation of TBK1 and underlie the hyper-sensitivity to
TNFa-induced damage exhibited by the optic nerve heads of
subjects with familial NTG.
How the enhanced interaction between OPTN[E50K] and
TBK1 might inﬂuence the activation of this protein kinaseby TNFa and other agonists, remains to be determined. It
could be argued that, by binding to TBK1 more strongly,
the OPTN[E50K] mutant recruits more TBK1 to K63-pUb-
RIP and/or other K63-pUb-proteins for activation by TNFa
and/or other agonists. Alternatively, by binding avidly to
TBK1, the OPTN[E50K] mutation may cause defective activa-
tion of TBK1 by sequestering TBK1 away from its other bind-
ing partners. In order to address these questions we are
therefore generating mice that express OPTN[E50K] instead
of the wild-type protein. This may lead to the development
of a mouse model for the NTG forms of POAG caused by
the OPTN[E50K] mutation and enable us to test the eﬀect of
potent inhibitors of TBK1 activity [26] in this model.
The suggestion that enhanced binding of TBK1 to OPT-
N[E50K] may underlie or contribute to POAG resulting from
this OPTN mutation diﬀers from that proposed recently by
Ashwell and co-workers [22]. These investigators reported that
TNFa-stimulated NFjB-dependent gene transcription was
greatly enhanced if the level of expression of OPTN was re-
duced with a miRNA, suggesting that OPTN might normally
function as a negative regulator of NFjB activation, perhaps
by competing with NEMO for binding to K63-pUb-RIP.
Moreover, since the OPTN[E50K] mutant was reported to
be expressed at a lower level than wild-type OPTN in dermal
ﬁbroblast cultures obtained from one patient with POAG
and one control subject [1], they suggested that it might be
the reduced expression of the OPTN[E50K] mutant which
causes NTG [22]. Further studies are clearly needed to deter-
mine whether POAG resulting from the OPTN[E50K] muta-
tion arises from increased activation of NFjB-dependent
gene transcription and/or abnormal activation of TBK1,
although these mechanisms are not necessarily mutually exclu-
sive, if the OPTN–TBK1 complex plays a role in suppressing
NFjB-dependent gene transcription.3. Materials and methods
3.1. Materials
The HA antibody and Interleukin-1b (IL-1b) were purchased from
Sigma, the OPTN antibody from Abcam, and the TBK1 antibody
from Cell Signalling Technologies, while the GST antibody was pro-
vided by the Division of Signal Transduction Therapy at Dundee. Glu-
tathione-Sepharose was obtained from GE Healthcare, while the IL-
1R cells were a gift from Tularic Inc., USA.
3.2. DNA cloning
Full length OPTN and TBK1 were cloned and inserted into
pEBG6P and pCMV5 to express GST and HA-tagged proteins, respec-
tively. TANK was cloned and also expressed in pCMV5. Site-directed
mutagenesis was carried out using the Quick Change method (Strata-
gene) but using KOD Hot Start Polymerase.
3.3. Cell culture, transfection, lysis, immunoprecipitation and
immunoblotting
IL-1R cells grown on 10 cm diameter dishes were transfected for
24 h using polyethyleneimine [27] and vectors expressing GST-tagged
and/or HA-tagged proteins. After depriving the cells of serum for
16 h, they were stimulated for 10 min with or without IL-1b (5 ng/
ml) and extracted in 0.5 ml ice cold lysis buﬀer [28]. To pull down
GST-tagged proteins, 1 mg of cell lysate protein was added to 20 ll
of glutathione-Sepharose beads, and after 1 h at 4 C the beads were
washed twice with 1 ml of cell lysis buﬀer plus 0.15 M NaCl and three
times with 1 ml cell lysis buﬀer. Bound proteins were released by dena-
turation in 1% SDS, subjected to SDS–PAGE, transferred to nitrocel-
lulose membranes and immunoblotted as described [29] with anti-HA.
S. Morton et al. / FEBS Letters 582 (2008) 997–1002 1001The membranes were stripped and re-probed with antibodies that rec-
ognise GST. To immunoprecipitate HA-tagged proteins, 1 mg cell ex-
tract protein was added to 10 ll of Protein G-Sepharose beads coupled
to 5 lg of HA antibody. After incubation for 2 h at 4 C the beads
were collected by centrifugation washed as described above and immu-
noblotted with anti-GST antibodies. The endogenous OPTN was
immunoprecipitated from 2 mg cell extract with anti-OPTN (4 lg,
1 h at 4 C) in a similar manner.
Acknowledgements: We thank the UK Medical Research Council, The
Royal Society, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline,
Merck and Co., Merck KGaA and Pﬁzer for ﬁnancial support. We are
also grateful to the Protein and Antibody Production teams of the
Division of Signal Transduction Therapy (coordinated by Hilary
McLaughlan and James Hastie) for the expression of OPTN and the
Sequencing service, University of Dundee, (www.dnaseq.co.uk) for
DNA sequencing.References
[1] Rezaie, T., Child, A., Hitchings, R., Brice, G., Miller, L., Coca-
Prados, M., Heon, E., Krupin, T., Ritch, R., Kreutzer, D., Crick,
R.P. and Sarfarazi, M. (2002) Adult-onset primary open-angle
glaucoma caused by mutations in optineurin. Science 295, 1077–
1079.
[2] Sarfarazi, M. and Rezaie, T. (2003) Optineurin in primary open
angle glaucoma. Ophthalmol. Clin. North. Am. 16, 529–
541.
[3] Aung, T., Ebenezer, N.D., Brice, G., Child, A.H., Prescott, Q.,
Lehmann, O.J., Hitchings, R.A. and Bhattacharya, S.S. (2003)
Prevalence of optineurin sequence variants in adult primary open
angle glaucoma: implications for diagnostic testing. J. Med.
Genet. 40, e101.
[4] Alward, W.L., Kwon, Y.H., Kawase, K., Craig, J.E., Hayreh,
S.S., Johnson, A.T., Khanna, C.L., Yamamoto, T., Mackey,
D.A., Roos, B.R., Aﬀatigato, L.M., Sheﬃeld, V.C. and Stone,
E.M. (2003) Evaluation of optineurin sequence variations in 1048
patients with open-angle glaucoma. Am. J. Ophthalmol. 136, 904–
910.
[5] Ayala-Lugo, R.M., Pawar, H., Reed, D.M., Lichter, P.R., Moroi,
S.E., Page, M., Eadie, J., Azocar, V., Maul, E., Ntim-Amponsah,
C., Bromley, W., Obeng-Nyarkoh, E., Johnson, A.T., Kijek,
T.G., Downs, C.A., Johnson, J.M., Perez-Grossmann, R.A.,
Guevara-Fujita, M.L., Fujita, R., Wallace, M.R. and Richards,
J.E. (2007) Variation in optineurin (OPTN) allele frequencies
between and within populations. Mol. Vis. 13, 151–163.
[6] Tezel, G. and Wax, M.B. (2000) Increased production of tumor
necrosis factor-alpha by glial cells exposed to simulated ischemia
or elevated hydrostatic pressure induces apoptosis in cocultured
retinal ganglion cells. J. Neurosci. 20, 8693–8700.
[7] Yuan, L. and Neufeld, A.H. (2000) Tumor necrosis factor-alpha:
a potentially neurodestructive cytokine produced by glia in the
human glaucomatous optic nerve head. Glia 32, 42–50.
[8] Schwamborn, K., Weil, R., Courtois, G., Whiteside, S.T. and
Israel, A. (2000) Phorbol esters and cytokines regulate the
expression of the NEMO-related protein, a molecule involved in
a NF-kappa B-independent pathway. J. Biol. Chem. 275, 22780–
22789.
[9] Cheng, G. and Baltimore, D. (1996) TANK, a co-inducer with
TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation.
Genes Dev. 10, 963–973.
[10] Fujita, F., Taniguchi, Y., Kato, T., Narita, Y., Furuya, A.,
Ogawa, T., Sakurai, H., Joh, T., Itoh, M., Delhase, M., Karin, M.
and Nakanishi, M. (2003) Identiﬁcation of NAP1, a regulatory
subunit of IkappaB kinase-related kinases that potentiates NF-
kappaB signaling. Mol. Cell Biol. 23, 7780–7793.
[11] Ryzhakov, G. and Randow, F. (2007) SINTBAD, a novel
component of innate antiviral immunity, shares a TBK1-bind-
ing domain with NAP1 and TANK. EMBO J. 26, 3180–
3190.
[12] Wiggs, J.L., Auguste, J., Allingham, R.R., Flor, J.D., Pericak-
Vance, M.A., Rogers, K., LaRocque, K.R., Graham, F.L.,
Broomer, B., Del Bono, E., Haines, J.L. and Hauser, M. (2003)Lack of association of mutations in optineurin with disease in
patients with adult-onset primary open-angle glaucoma. Arch.
Ophthalmol. 121, 1181–1183.
[13] McWhirter, S.M., Fitzgerald, K.A., Rosains, J., Rowe, D.C.,
Golenbock, D.T. and Maniatis, T. (2004) IFN-regulatory factor
3-dependent gene expression is defective in Tbk1-deﬁcient mouse
embryonic ﬁbroblasts. Proc. Natl. Acad. Sci. USA 101, 233–
238.
[14] Hemmi, H., Takeuchi, O., Sato, S., Yamamoto, M., Kaisho, T.,
Sanjo, H., Kawai, T., Hoshino, K., Takeda, K. and Akira, S.
(2004) The roles of two IkappaB kinase-related kinases in
lipopolysaccharide and double stranded RNA signaling and viral
infection. J. Exp. Med. 199, 1641–1650.
[15] Matsui, K., Kumagai, Y., Kato, H., Sato, S., Kawagoe, T.,
Uematsu, S., Takeuchi, O. and Akira, S. (2006) Cutting edge: role
of TANK-binding kinase 1 and inducible IkappaB kinase in IFN
responses against viruses in innate immune cells. J. Immunol. 177,
5785–5789.
[16] Chariot, A., Leonardi, A., Muller, J., Bonif, M., Brown, K. and
Siebenlist, U. (2002) Association of the adaptor TANK with the I
kappa B kinase (IKK) regulator NEMO connects IKK complexes
with IKK epsilon and TBK1 kinases. J. Biol. Chem. 277, 37029–
37036.
[17] Zhao, T., Yang, L., Sun, Q., Arguello, M., Ballard, D.W.,
Hiscott, J. and Lin, R. (2007) The NEMO adaptor bridges the
nuclear factor-kappaB and interferon regulatory factor signaling
pathways. Nature Immunol. 8, 592–600.
[18] Wu, C.J., Conze, D.B., Li, T., Srinivasula, S.M. and Ashwell, J.D.
(2006) Sensing of Lys 63-linked polyubiquitination by NEMO is a
key event in NF-kappaB activation [corrected]. Nat. Cell. Biol. 8,
398–406.
[19] Ea, C.K., Deng, L., Xia, Z.P., Pineda, G. and Chen, Z.J. (2006)
Activation of IKK by TNFalpha requires site-speciﬁc ubiquiti-
nation of RIP1 and polyubiquitin binding by NEMO. Mol. Cell
22, 245–257.
[20] Doﬃnger, R., Smahi, A., Bessia, C., Geissmann, F., Feinberg, J.,
Durandy, A., Bodemer, C., Kenwrick, S., Dupuis-Girod, S.,
Blanche, S., Wood, P., Rabia, S.H., Headon, D.J., Overbeek,
P.A., Le Deist, F., Holland, S.M., Belani, K., Kumararatne, D.S.,
Fischer, A., Shapiro, R., Conley, M.E., Reimund, E., Kalhoﬀ, H.,
Abinun, M., Munnich, A., Israel, A., Courtois, G. and Casanova,
J.L. (2001) X-linked anhidrotic ectodermal dysplasia with immu-
nodeﬁciency is caused by impaired NF-kappaB signaling. Nat.
Genet. 27, 277–285.
[21] Filipe-Santos, O., Bustamante, J., Haverkamp, M.H., Vinolo, E.,
Ku, C.L., Puel, A., Frucht, D.M., Christel, K., von Bernuth, H.,
Jouanguy, E., Feinberg, J., Durandy, A., Senechal, B., Chapgier,
A., Vogt, G., de Beaucoudrey, L., Fieschi, C., Picard, C., Garfa,
M., Chemli, J., Bejaoui, M., Tsolia, M.N., Kutukculer, N.,
Plebani, A., Notarangelo, L., Bodemer, C., Geissmann, F., Israel,
A., Veron, M., Knackstedt, M., Barbouche, R., Abel, L.,
Magdorf, K., Gendrel, D., Agou, F., Holland, S.M. and
Casanova, J.L. (2006) X-linked susceptibility to mycobacteria is
caused by mutations in NEMO impairing CD40-dependent IL-12
production. J. Exp. Med. 203, 1745–1759.
[22] Zhu, G., Wu, C.J., Zhao, Y. and Ashwell, J.D. (2007) Optineurin
negatively regulates TNFalpha- induced NF-kappaB activation
by competing with NEMO for ubiquitinated RIP. Curr. Biol. 17,
1438–1443.
[23] Bonnard, M., Mirtsos, C., Suzuki, S., Graham, K., Huang, J., Ng,
M., Itie, A., Wakeham, A., Shahinian, A., Henzel, W.J., Elia,
A.J., Shillinglaw, W., Mak, T.W., Cao, Z. and Yeh, W.C. (2000)
Deﬁciency of T2K leads to apoptotic liver degeneration and
impaired NF-kappaB-dependent gene transcription. Embo J. 19,
4976–4985.
[24] Kuai, J., Wooters, J., Hall, J.P., Rao, V.R., Nickbarg, E., Li, B.,
Chatterjee-Kishore, M., Qiu, Y. and Lin, L.L. (2004) NAK is
recruited to the TNFR1 complex in a TNFalpha-dependent
manner and mediates the production of RANTES: identiﬁcation
of endogenous TNFR-interacting proteins by a proteomic
approach. J. Biol. Chem. 279, 53266–53271.
[25] Li, Y., Kang, J. and Horwitz, M.S. (1998) Interaction of an
adenovirus E3 14.7-kilodalton protein with a novel tumor
necrosis factor alpha-inducible cellular protein containing leucine
zipper domains. Mol. Cell Biol. 18, 1601–1610.
1002 S. Morton et al. / FEBS Letters 582 (2008) 997–1002[26] Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, J., McLauch-
lan, H., Klevernic, I., Arthur, S., Alessi, D. and Cohen, P. (2007)
The selectivity of protein kinase inhibitors; a further update.
Biochem. J. 408, 297–315.
[27] Durocher, Y., Perret, S. and Kamen, A. (2002) High-level and
high-throughput recombinant protein production by transient
transfection of suspension-growing human 293-EBNA1 cells.
Nucleic Acids Res. 30, E9.[28] Staﬀord, M.J., Morrice, N.A., Peggie, M.W. and Cohen, P. (2006)
Interleukin-1 stimulated activation of the COT catalytic subunit
through the phosphorylation of Thr290 and Ser62. FEBS Lett.
580, 4010–4014.
[29] Morton, S., Davis, R.J., McLaren, A. and Cohen, P. (2003) A
reinvestigation of the multisite phosphorylation of the transcrip-
tion factor c-Jun. EMBO J. 22, 3876–3886.
